Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

EntreMed Sweetens Private Placement with China Rights to Cancer Drug

publication date: Sep 10, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
EntreMed raised $5.1 million in a private placement that featured an unusual sweetener for the investors: a 16-month option on the China marketing rights to EntreMed’s lead drug candidate. The funding placed 1,886,662 units at a price of $2.70 (EntreMed closed at $3.00), each unit consisting of 1 share of stock and a three-year warrant for .2 share – the upshot being that outside of the marketing option, the transaction was structured as a normal private placement.  More details....

Stock Symbol: (NSDQ: ENMD)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners